Schrödinger GmbH

Schrödinger (NASDAQ: SDGR) is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Schrödinger has a growing pipeline of early-stage assets and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. In addition, the company has deep partnerships and collaborations in such fields as biotechnology, pharmaceuticals, chemicals, and electronics. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science.

The company's full product offerings range from general molecular modeling programs to a comprehensive suite of drug discovery and materials design software. Schrödinger is continually developing enterprise level software that can be deployed throughout an entire research organization, and the company is committed to providing integrated software solutions and services that truly meet its customers’ needs. Schrödinger wants to empower researchers around the world to achieve their goals of improving human health and quality of life through advanced computational techniques that transform the way chemists design compounds and materials. By building and deploying breakthrough scientific software solutions and forming collaborations and partnerships, Schrödinger helps scientists accelerate their research and development activities, reduce costs, and make novel discoveries that might otherwise not be possible.

Founded in 1990, Schrödinger has over 450 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.